WVU Today | June 12, 2023
Drugs used to treat rare conditions are earning pharmaceutical companies almost as much as those marketed to the general public, according to a researcher at West Virginia University. Sean Tu, a College of Law professor found lucrative so-called “orphan” drugs earn manufacturing tax credits, have longer patent exclusivities and face easier Food and Drug Administration review.